Abstract
The generation of this novel humanized SRG rat model could allow for a more permissive host system to test existing and novel immunomodulatory strategies for the treatment of human disease.
Transplantation of human cancer cell lines:
The speci ed number of cells for each cell line were mixed with Geltrex® or Cultrex® 1:1 and transplanted subcutaneously in the hind ank. VCaP prostate cancer cells -10x106. Tumors were measured three times weekly and recorded in StudyLog to determine tumor growth kinetics. Animals were euthanized when the tumors reached humane endpoints. Serum PSA was measured by ELISA (ALPCO) on blood collected weekly after inoculation. Transplantation of PDX tissues: Non-small cell lung cancer PDX tumor fragments were obtained fresh from patients at the Markey Cancer Center through the University of Kentucky Biospecimen Procurement and Translational Pathology Shared Resource Facility under IRB 17-0513-P3K. Each tissue was cut into 2mm x 2mm pieces and immediately implanted subcutaneously using a trocar into SRG rats or NSG mice. For serial transplants, tumors were removed aseptically and cut into 2mm x 2mm pieces and transplanted, ash frozen, or xed in 10% NBF. Immune humanization with PBMCs: Human PBMCs were purchased from Stem Express. 50x106 viable cells as determined flow cytometry analysis using propidium iodide were transplanted via the tail vein in SRG rats at 8-10 weeks of age. FACS analysis was performed to assess circulating human CD45+, human CD3+, human CD4+, human CD8+ and human CD20+ cells.
Figure1. VCaP tumor kinetics in the SRG rat.
VCaP cancer cells, known to have poor engraftment rates and kinetics in immunodeficient mice, thrived in the SRG rat. The cells were inoculated in the ank region at a density of 10x106 cells per rat in a 1:1 solution of cell culture media and 5mg/ml Cultrex. Engraftment rate was 75%.
Top: Tumor growth. Each line represents growth in a single animal.
Bottom: Serum PSA. Blood was collected prior to inoculation and then weekly after inoculation. Serum was separated and assessed for PSA. Serum PSA is highly correlative with VCaP tumor growth in the SRG rat. Cryopreserved human PBMCs were purchased from Stem Express. Viability was determined by staining the cell suspension with propidium iodide and analyzing on a flow cytometer. 50x10 6 viable human PBMCs in 500µl PBS were injected into the tail vein of 3 male and 3 female SRG rats at 8-10 weeks of age. Peripheral blood was analyzed for the presence of human CD45+, CD3+, CD4+, and CD8+ cells at 3, 7, 14, 28, 54, and 70 days post-injection. By 4 weeks post-transplant, recipients had an average of 29% circulating human CD45+ cells. As of 10 weeks post-transplant, recipients have up to 46% human CD45+ cells and remain healthy. This study is currently ongoing to assess longevity of the human cells and the incidence of graft vs. host disease.
